Natalia L. Acosta‐Vega
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalia L. Acosta‐Vega has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
A. Dash
Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, USA
1 shared publication- Alba Lucia Combita
Instituto Nacional de Cancerologia
1 shared publication - Alberto Gómez
Pontificia Universidad Javeriana
1 shared publication - David J. Marcinek
Department of Radiology University of Washington Seattle Washington USA
1 shared publication G. Miranda
Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, USA
1 shared publicationH. L. Kerr
Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, USA
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Muscle mitochondria, function, mass, and quality of life in prostate cancer during androgen deprivation therapy
Prostate cancer (PCa) negatively impacts muscle mass, physical function, and patient-reported outcomes (PROs), while androgen deprivation therapy (ADT) exacerbates these effects. Mitochondria are important for muscle function but their role in PCa patients undergoing ADT is not well-established. Our study characterizes the relationship between muscle mass, strength, endurance, PROs, and mitochondria in PCa patients over six months of ADT. Prior to ADT, higher mitochondrial function and endurance are associated with better PROs; whereas higher appendicular lean mass (ALM) correlate with worse PROs. Greater baseline VO 2 peak and mitochondrial function predict smaller declines in ALM, muscle function, and PROs. Proteomics analysis indicates mitochondrial dysfunction and upregulation of extracellular matrix organization, inflammation and coagulation-related pathways with ADT. Our findings suggest that mitochondrial function plays a role in muscle endurance and PROs in PCa. These data may help select patients and outcomes for clinical trials. Future studies should test whether targeting mitochondria can improve physical function and PROs in PCa.
- 27 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMuscle mitochondria, function, mass, and quality of life in prostate cancer during androgen deprivation therapy
Prostate cancer (PCa) negatively impacts muscle mass, physical function, and patient-reported outcomes (PROs), while androgen deprivation therapy (ADT) exacerbates these effects. Mitochondria are important for muscle function but their role in PCa patients undergoing ADT is not well-established. Our study characterizes the relationship between muscle mass, strength, endurance, PROs, and mitochondria in PCa patients over six months of ADT. Prior to ADT, higher mitochondrial function and endurance are associated with better PROs; whereas higher appendicular lean mass (ALM) correlate with worse PROs. Greater baseline VO 2 peak and mitochondrial function predict smaller declines in ALM, muscle function, and PROs. Proteomics analysis indicates mitochondrial dysfunction and upregulation of extracellular matrix organization, inflammation and coagulation-related pathways with ADT. Our findings suggest that mitochondrial function plays a role in muscle endurance and PROs in PCa. These data may help select patients and outcomes for clinical trials. Future studies should test whether targeting mitochondria can improve physical function and PROs in PCa.
- Open Access
- 3 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (4) , 4306-4320
Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer
Background: The role of ERG‐status molecular subtyping in prognosis of prostate cancer (PCa) is still under debate. In this study, we identified differentially expressed genes (DEGs) according to ERG‐status to explore their enriched pathways and implications in prognosis in Hispanic/Latino PCa patients.Methods: RNA from 78 Hispanic PCa tissues from radical prostatectomies (RP) were used for RNA‐sequencing. ERGhigh/ERGlow tumor groups were determined based on the 1.5‐fold change median expression in non‐tumor samples. DEGs with a False Discovery Rate (FDR) < 0.01 and a fold change >2 were identified between ERGhigh and ERGlow tumors and submitted to enrichment analysis in MetaCore. Survival and association analyses were performed to evaluate biochemical recurrence (BCR)‐free survival.Results: The identification of 150 DEGs between ERGhigh and ERGlow tumors revealed clustering of most of the non‐BCR cases (60%) into de ERGhigh group and most of the BCR cases (60.8%) in ERGlow group. Kaplan–Meier survival curves showed a worst BCR‐free survival for ERGlow patients, and a significant reduced risk of BCR was observed for ERGhigh cases (OR = 0.29 (95%CI, 0.10–0.8)). Enrichment pathway analysis identified metabolic‐related pathways, such as the renin‐angiotensin system and angiotensin maturation system, the linoleic acid metabolism, and polyamines metabolism in these ERG groups.Conclusions: ERGlow tumor cases were associated with poor BCR‐free survival in our Hispanic/Latino patients, with metabolism‐related pathways altered in the BCR progression.Impact: Our findings suggest the need to dissect the role of diet, metabolism, and lifestyle as risk factors for more aggressive PCa subtypes.
- 3 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (4) , 4306-4320
Open AccessMetabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer
Background: The role of ERG‐status molecular subtyping in prognosis of prostate cancer (PCa) is still under debate. In this study, we identified differentially expressed genes (DEGs) according to ERG‐status to explore their enriched pathways and implications in prognosis in Hispanic/Latino PCa patients.Methods: RNA from 78 Hispanic PCa tissues from radical prostatectomies (RP) were used for RNA‐sequencing. ERGhigh/ERGlow tumor groups were determined based on the 1.5‐fold change median expression in non‐tumor samples. DEGs with a False Discovery Rate (FDR) < 0.01 and a fold change >2 were identified between ERGhigh and ERGlow tumors and submitted to enrichment analysis in MetaCore. Survival and association analyses were performed to evaluate biochemical recurrence (BCR)‐free survival.Results: The identification of 150 DEGs between ERGhigh and ERGlow tumors revealed clustering of most of the non‐BCR cases (60%) into de ERGhigh group and most of the BCR cases (60.8%) in ERGlow group. Kaplan–Meier survival curves showed a worst BCR‐free survival for ERGlow patients, and a significant reduced risk of BCR was observed for ERGhigh cases (OR = 0.29 (95%CI, 0.10–0.8)). Enrichment pathway analysis identified metabolic‐related pathways, such as the renin‐angiotensin system and angiotensin maturation system, the linoleic acid metabolism, and polyamines metabolism in these ERG groups.Conclusions: ERGlow tumor cases were associated with poor BCR‐free survival in our Hispanic/Latino patients, with metabolism‐related pathways altered in the BCR progression.Impact: Our findings suggest the need to dissect the role of diet, metabolism, and lifestyle as risk factors for more aggressive PCa subtypes.